EiRx Therapeutics, based in Cork, said it has requested a suspension of trading in its shares on AIM, pending clarification of its financial position.

THE funding package put in place by EiRx Therapeutics is sufficient and will allow it to advance its drug development programme over the next 12 months, according to the Cork-based company.

Companies reporting results next week include:

Publicly-quoted pharmaceutical research company EiRx Therapeutics said venture capital group Billam, one of its major shareholders, would raise almost €500,000 from the sale of some of its stake.